Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Aclaris Therapeutics, Inc. | acrs-20161231ex3212699d8.htm |
| EX-31.2 - EX-31.2 - Aclaris Therapeutics, Inc. | acrs-20161231ex312cd1806.htm |
| EX-31.1 - EX-31.1 - Aclaris Therapeutics, Inc. | acrs-20161231ex311c7fc35.htm |
| EX-10.25 - EX-10.25 - Aclaris Therapeutics, Inc. | acrs-20161231ex10258cf6d.htm |
| EX-10.24 - EX-10.24 - Aclaris Therapeutics, Inc. | acrs-20161231ex10246370f.htm |
| 10-K - 10-K - Aclaris Therapeutics, Inc. | acrs-20161231x10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-214384) and Form S-8 (No. 333-210379, No. 333-207434) of our report dated March 15, 2017 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
March 15, 2017